Vildagliptin – the unique DPP-4 inhibitor of the class Review article
Article Sidebar
Published:
Dec 22, 2022
Keywords:
vildagliptin, DPP-4 inhibitors, incretins, type 2 diabetes mellitus, combination therapy
Main Article Content
Abstract
Vildagliptin is the only DPP-4 inhibitor to be taken twice daily. Although Cardiovascular Outcome Trial required by FDA was not conducted for vidalagliptin, it’s cardiovascular safety profile was demonstrated in many metaanalyses and observational studies already published. The results of VERIFY study are of particular interest, as the metformin and vildagliptin combination therapy implemented at diabetes type 2 diagnosis provides durability of action as well as postpone the need for insulin initiation.
Article Details
How to Cite
Dzida , G. (2022). Vildagliptin – the unique DPP-4 inhibitor of the class. Medycyna Faktow (J EBM). Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2330
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Golightly LK, Drayna CC , McDermott MT. Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. Clin Pharmacokinet. 2012; 51: 501-14. http://doi.org/10.1007/BF03261927.
2. Ou SM, Shih CJ , Chao PW et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med. 2015; 163: 663-72. http://doi.org/10.7326/M15-0308.
3. Kaneko M, Narukawa M. Meta-Analysis of Dipeptidyl Peptidase-4 Inhibitors Use and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. Diabetes Res Clin Pract. 2016; 116: 171-82. http://doi.org/10.1016/j.diabres.2016.04.012.
4. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. 2022 Guidelines on the Management of Patients with Diabetes. APosition of Diabetes Poland. Curr Top Diabetes. 2022; 2: 1-134.
5. Matthews D, Del Prato S, Mohan V et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020; 11(11): 2465- 2476. https://doi.org/10. 1007/s13300-020-00926-7.
6. Matthews DR, Paldánius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519-1529. https://doi.org/10.1016/S0140-6736(19)32131-2.
7. Chan JCN, Paldánius PM, Mathieu C et al. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab. 2021; 23(1): 245-251. https://doi.org/10.1111/dom.14192.
8. Davies MJ, Aroda VR, Collins BS et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA ) and the European Association for the Study of Diabetes (EASD). D iabetologia. 2022; 65: 1925-1966. https://doi.org/10.1007/s00125-022-05787-2.
2. Ou SM, Shih CJ , Chao PW et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med. 2015; 163: 663-72. http://doi.org/10.7326/M15-0308.
3. Kaneko M, Narukawa M. Meta-Analysis of Dipeptidyl Peptidase-4 Inhibitors Use and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. Diabetes Res Clin Pract. 2016; 116: 171-82. http://doi.org/10.1016/j.diabres.2016.04.012.
4. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. 2022 Guidelines on the Management of Patients with Diabetes. APosition of Diabetes Poland. Curr Top Diabetes. 2022; 2: 1-134.
5. Matthews D, Del Prato S, Mohan V et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020; 11(11): 2465- 2476. https://doi.org/10. 1007/s13300-020-00926-7.
6. Matthews DR, Paldánius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519-1529. https://doi.org/10.1016/S0140-6736(19)32131-2.
7. Chan JCN, Paldánius PM, Mathieu C et al. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab. 2021; 23(1): 245-251. https://doi.org/10.1111/dom.14192.
8. Davies MJ, Aroda VR, Collins BS et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA ) and the European Association for the Study of Diabetes (EASD). D iabetologia. 2022; 65: 1925-1966. https://doi.org/10.1007/s00125-022-05787-2.